logo
Florida hotels might've gotten Italian mini pastries from Canada in salmonella outbreak

Florida hotels might've gotten Italian mini pastries from Canada in salmonella outbreak

Yahoo09-02-2025

Those cute little Italian pastry bites at a bakery, hotel cafe or the most recent catered event you attended might be part of a salmonella outbreak in the United States and Canada.
Here's what you need to know.
READ MORE: Salmonella causes a tahini recall in Florida, North Carolina, California, 19 total states
This salmonella outbreak involves mini pastries made in Italy, sent to the United States from Canada by Importations Piu Che Dolci and sold under the Sweet Cream brand.
They were sold to two distributors with centers in Florida, Pennsylvania, New York and New Jersey, which then flipped them to hotel cafes, restaurants, bakeries, caterers and institutional customers. Piu Che Dolci recalled the pastries sold in boxed cases and 30-piece trays with best by dates from June 17, 2025 through Nov. 15, 2025.
'Pastries were sold to foodservice locations and may have been sold individually or in smaller packages, with or without a label that may not bear the same brand, product name, or best by date,' Thursday's FDA advisory said. 'Consumers who are unsure if they have purchased the recalled products are advised to contact their retailer.
'The food service customers who received the recalled product have been contacted directly by the distributing firms, and the recalled product should no longer be available for sale.'
READ MORE: Oysters sold by Publix, Walmart and others recalled after 'norovirus-like' illnesses
Though the distributors had locations in Florida, New York, New Jersey and Pennsylvania, none of the documented sicknesses linked to the mini-pastries are in Florida. The other three distribution states, North Carolina, California, Illinois and Massachusetts have the 18 people counted in this outbreak. One person has been hospitalized.
On Jan. 21, the FDA learned of an outbreak of salmonella enteritidis, which is the same strain under investigation in Canada.
'As part of this investigation, FDA conducted traceback for one of the U.S. cases and identified that they were served recalled Sweet Cream-brand mini pastries at a restaurant prior to becoming sick,' the FDA said.
Salmonella is one of the most common foodborne illnesses, hitting 1.35 million people in the United States annually, the CDC says. Salmonella usually brings four to seven days of diarrhea that might be bloody, vomiting, nausea, stomachaches and headaches. About 1.95 percent of people need hospitalization. Most people recover without medical attention so sicknesses in salmonella outbreaks tend to be undercounted.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SONU Band by SoundHealth Receives Pediatric FDA Approval
SONU Band by SoundHealth Receives Pediatric FDA Approval

Business Wire

timean hour ago

  • Business Wire

SONU Band by SoundHealth Receives Pediatric FDA Approval

SAN FRANCISCO--(BUSINESS WIRE)-- SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, announced it received United States Food and Drug Administration (FDA) approval for pediatric use of its groundbreaking SONU Band. SONU is the world's first FDA De Novo authorized, AI-enabled, wearable medical device for at-home treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis. This expanded approval makes SONU the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up, providing a safe alternative to pharmaceutical treatments. SoundHealth has developed the world's first FDA-approved, wearable device for children 12 and up that offers a drug-free, safe solution for treating nasal congestion and allergies. Share 'SONU offers a promising new option for children struggling with chronic nasal congestion. As a non-invasive, drug-free solution, it addresses a significant need among families looking for safe, effective alternatives to traditional therapies—particularly those involving steroids or medications with side effects,' said Dr. Alan Greene, Adjunct Professor of Pediatrics, Stanford University; Principal Investigator. Clinically proven to be fast-acting and effective, over 80 percent of SONU patients reported improvement in their nasal symptoms. SONU represents a brand-new category of safe and rapid relief therapies for nasal congestion and spares patients from the side effects commonly associated with other treatment options. 'Nasal congestion and allergies don't have to be life-altering,' said Dr. Paramesh Gopi, founder and CEO of SoundHealth. 'Our team of scientists, engineers and medical professionals has truly revolutionized respiratory health with AI-powered sound therapy. We are thrilled to now be able to offer relief from congestion to children and will continue to work toward helping people breathe better.' SONU is easy, convenient and pleasant to use for patients. Using SoundHealth's proprietary AI technology, the SONU app scans the patient's face using a smartphone and creates a digital map of their sinuses, calculating their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU Band around their head, turns it on and the band delivers frequencies tailored to the patient based on the app's calculations. The science behind SONU: SONU uses acoustic vibrational energy to provide personalized relief for nasal congestion. The band produces resonant sound waves that gently vibrate the nasal cavity. These micro vibrations help reduce swelling, open nasal passages and drain healthy mucus. Acoustic vibration associated with humming has been shown to decrease symptoms of nasal congestion, possibly through modulation of autonomic inputs to the nasal mucosa or through nitric oxide activity, which may in turn exert a decongestant and anti-inflammatory effect on the nasal passages. Using personalized, relaxing sound waves, SONU provides relief of nasal symptoms in 15 minutes or less. SONU is the only FDA-approved device equivalent to or better than the leading nasal steroid spray, calming down symptoms of allergies, inflammation and congestion. For more information, please visit About SoundHealth SoundHealth is a medical technology company that harnesses the power of artificial intelligence and medical science to improve respiratory and mental health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. Visit

SONU Band by SoundHealth Receives Pediatric FDA Approval
SONU Band by SoundHealth Receives Pediatric FDA Approval

Yahoo

timean hour ago

  • Yahoo

SONU Band by SoundHealth Receives Pediatric FDA Approval

SoundHealth has developed the world's first FDA-approved, wearable device for children 12 and up that offers a drug-free, safe solution for treating nasal congestion and allergies. SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, announced it received United States Food and Drug Administration (FDA) approval for pediatric use of its groundbreaking SONU Band. SONU is the world's first FDA De Novo authorized, AI-enabled, wearable medical device for at-home treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis. This expanded approval makes SONU the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up, providing a safe alternative to pharmaceutical treatments. "SONU offers a promising new option for children struggling with chronic nasal congestion. As a non-invasive, drug-free solution, it addresses a significant need among families looking for safe, effective alternatives to traditional therapies—particularly those involving steroids or medications with side effects," said Dr. Alan Greene, Adjunct Professor of Pediatrics, Stanford University; Principal Investigator. Clinically proven to be fast-acting and effective, over 80 percent of SONU patients reported improvement in their nasal symptoms. SONU represents a brand-new category of safe and rapid relief therapies for nasal congestion and spares patients from the side effects commonly associated with other treatment options. "Nasal congestion and allergies don't have to be life-altering," said Dr. Paramesh Gopi, founder and CEO of SoundHealth. "Our team of scientists, engineers and medical professionals has truly revolutionized respiratory health with AI-powered sound therapy. We are thrilled to now be able to offer relief from congestion to children and will continue to work toward helping people breathe better." SONU is easy, convenient and pleasant to use for patients. Using SoundHealth's proprietary AI technology, the SONU app scans the patient's face using a smartphone and creates a digital map of their sinuses, calculating their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU Band around their head, turns it on and the band delivers frequencies tailored to the patient based on the app's calculations. The science behind SONU: SONU uses acoustic vibrational energy to provide personalized relief for nasal congestion. The band produces resonant sound waves that gently vibrate the nasal cavity. These micro vibrations help reduce swelling, open nasal passages and drain healthy mucus. Acoustic vibration associated with humming has been shown to decrease symptoms of nasal congestion, possibly through modulation of autonomic inputs to the nasal mucosa or through nitric oxide activity, which may in turn exert a decongestant and anti-inflammatory effect on the nasal passages. Using personalized, relaxing sound waves, SONU provides relief of nasal symptoms in 15 minutes or less. SONU is the only FDA-approved device equivalent to or better than the leading nasal steroid spray, calming down symptoms of allergies, inflammation and congestion. For more information, please visit About SoundHealth SoundHealth is a medical technology company that harnesses the power of artificial intelligence and medical science to improve respiratory and mental health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. Visit View source version on Contacts Jared@

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Yahoo

time2 hours ago

  • Yahoo

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store